
DENTSPLY SIRONA (XRAY) Stock Forecast & Price Target
DENTSPLY SIRONA (XRAY) Analyst Ratings
Bulls say
Dentsply Sirona is poised for positive financial growth, evidenced by a reported sales increase of 2.8% in Europe, alongside a 1.8% organic growth rate, indicating steady demand in the dental market. Additionally, the company's subsidiary, Wellspect Healthcare, demonstrated robust performance with $81 million in revenue, reflecting an 8.6% reported increase and 6.7% organic growth, suggesting strong product acceptance and market positioning. The firm is positioned to benefit from accelerating revenue growth projected in the mid-single digits, driven by improved market share in clear aligners, a recovering implants segment, and margin enhancements, which could contribute to faster earnings per share growth.
Bears say
Dentsply Sirona reported a substantial miss in its profitability, with adjusted EPS of $0.26 significantly lower than the expected $0.43, primarily due to disappointing revenue and increased operating expenses. The connected technology solutions segment experienced an 8.3% decline in revenue, highlighting ongoing challenges in revenue generation and gross margin performance, which fell short of consensus estimates. Moreover, the Byte shutdown led to a $62 million revenue loss, exacerbating the firm's already weak financial results, characterized by declining gross margins and rising operating costs across both SG&A and R&D.
This aggregate rating is based on analysts' research of DENTSPLY SIRONA and is not a guaranteed prediction by Public.com or investment advice.
DENTSPLY SIRONA (XRAY) Analyst Forecast & Price Prediction
Start investing in DENTSPLY SIRONA (XRAY)
Order type
Buy in
Order amount
Est. shares
0 shares